Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Pipethanate Ethobromide→

Pipethanate Ethobromide PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
23182-46-9
Molecular formula
C23H30BrNO3
Molecular weight
448.4 g/mol
Drug class
Quaternary ammonium antimuscarinic antispasmodic
Mechanism of action
The pipethanate cation produces antimuscarinic smooth-muscle relaxation by antagonising acetylcholine-mediated muscarinic receptor signalling in the gastrointestinal tract. Ethobromide is the counter-ion; it does not create a different API pharmacology.
Indications / reported uses
  • Symptomatic relief of gastrointestinal smooth-muscle spasm in countries where pipethanate products are authorised; current product status and precise indications require confirmation from local product information

Sources: NLM MeSH — Pipethanate · PubChem — Pipethanate

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Quaternary ammonium antimuscarinic antispasmodic

Mechanism of action

The pipethanate cation produces antimuscarinic smooth-muscle relaxation by antagonising acetylcholine-mediated muscarinic receptor signalling in the gastrointestinal tract. Ethobromide is the counter-ion; it does not create a different API pharmacology.

General use cases

  • Symptomatic relief of gastrointestinal smooth-muscle spasm in countries where pipethanate products are authorised; current product status and precise indications require confirmation from local product information
Active moiety: pipethanate (Simple salt/counter-ion form; shares the same API pharmacology and general use cases.)

Pipethanate is the pharmacologically active antispasmodic cation; bromide is the counter-ion. Do not assign a distinct indication solely because of the bromide salt.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Pipethanate Ethobromide PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Pipethanate Ethobromide Permitted Daily Exposure (PDE) report (the Pipethanate Ethobromide PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Pipethanate Ethobromide Occupational Exposure Limit (OEL) report (the Pipethanate Ethobromide OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.